(Q37802798)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

title

Temozolomide for corticotroph pituitary adenomas refractory to standard therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

0 references

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

5

Edward A Neuwelt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Troy H Dillard

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

S Humayun Gultekin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Johnny B Delashaw

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Chris G Yedinak

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

1 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

80-91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11102-010-0264-1

14 January 2020

exact match

0 references

cites work

An approach to the management of patients with residual Cushing's disease

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

A novel use of temozolomide in a patient with malignant prolactinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Pituitary carcinoma presenting with multiple metastases: case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Clinical review: Diagnosis and management of pituitary carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Inhibition of angiogenesis by non-toxic doses of temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Use of temozolomide in aggressive pituitary tumors: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Treatment of Nelson's syndrome with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Temozolomide-induced myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Pituitary carcinoma: a clinicopathologic study of 15 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Radiosurgery for Cushing's disease after failed transsphenoidal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Radiation therapy and stereotactic radiosurgery for the treatment of Cushing's disease: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0264-1

Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome

21 January 2018

1 reference

12 December 2020

Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression

1 reference

12 December 2020

SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases

1 reference

12 December 2020

Long-term response of pituitary carcinoma to temozolomide. Report of two cases.

1 reference

12 December 2020

Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm

1 reference

12 December 2020

Early repeat surgery for persistent Cushing's disease

1 reference

12 December 2020

Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas

1 reference

12 December 2020

Temozolomide: a novel treatment for pituitary carcinoma

1 reference

12 December 2020

Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma

1 reference

12 December 2020

Treatment options for Cushing disease after unsuccessful transsphenoidal surgery

1 reference

12 December 2020

Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model

1 reference

12 December 2020

Radiotherapy in the management of giant pituitary adenomas

1 reference

12 December 2020

Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings

1 reference

12 December 2020

Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.

1 reference

12 December 2020

Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly

1 reference

12 December 2020

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

1 reference

12 December 2020

Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

1 reference

12 December 2020

Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series

1 reference

12 December 2020

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

12 December 2020

10.1007/S11102-010-0264-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20972839%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference